Eligible Registrants – AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Concurrent Session 5: Targeting the RAS/MAP Kinase Pathway

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 6 of 6
The KRASG12C inhibitor, MRTX849, provides insight toward therapeutic susceptibility of KRAS mutant cancers
James G Christensen
Mirati Therapeutics, San Diego, CA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
A phase 1 clinical trial evaluating the pharmacokinetics (PK), safety, and clinical activity of MRTX849, a mutant-selective small molecule KRASG12C inhibitor, in advanced solid tumors
Pasi A Jänne
Dana-Farber Cancer Institute, Boston, MA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Chairperson
Ruth Plummer
Northern Institute for Cancer Research, Newcastle, United Kingdom
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Next generation strategies to overcome adaptive resistance to MAPK-directed therapies
Poulikos Poulikakos
Icahn School of Medicine at Mount Sinai, New York, NY, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction
Benjamin Bader
Bayer AG, Berlin, Germany
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Therapeutic response and resistance to pan-RAF inhibition: From bench to clinic and back
Shiva Malek
Genentech, Inc., South San Francisco, CA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 6 of 6